1 minute of reading
CHARLOTTE, NC 🇧🇷 Data from a real-world study revealed that Somryst digital therapeutic prescription treatment achieved reductions in symptoms of insomnia, anxiety and depression, according to a last-minute poster at the SLEEP meeting.
Somryst is the only FDA-cleared prescription digital therapeutic for the treatment of chronic insomnia, manufacturer Pear Therapeutics said in a related press release.
“Chronic insomnia is often associated with depression and anxiety, so it is important to assess the impact of insomnia treatment on such psychiatric comorbidities,” Yuri Maricich, MD, MBA, chief medical officer and head of development at Pear Therapeutics, said in the statement. “We sought to measure not only the impact on nocturnal sleep, but also the effect on daytime commitment.”
According to the release, the DREAM trial is a remote, virtual, open-label, decentralized trial that enrolled 993 US adult patients, ages 22 to 75, with chronic insomnia who had access to a mobile device. Results showed that those treated with Somryst for 9 weeks with cognitive-behavioral therapy recommended for insomnia had reductions in symptoms of insomnia severity immediately after treatment and 6 months later. Scores for depression and anxiety also decreased significantly, the researchers reported.
Interim analysis of data in early 2022 revealed that the mean Insomnia Severity Index score (scale 0-28) at baseline among those enrolled in the study was 23.9, which improved to 14.5 at the end of treatment and 16.7 after 6 months. The mean score on the Patient Health Questionnaire depression scale (0-24) at baseline among participants with severe depression was 21.4, which decreased to 12.7 at the end of treatment and maintained a score of 12.3 in 6 months. Finally, the mean Generalized Anxiety Disorder score (0-21) among participants with severe anxiety was 17.6 at baseline and 10.8 at end of treatment and at 6 months.
“We are encouraged by the lasting response seen in this real-world interim analysis of cognitive behavioral therapy for insomnia provided by Somryst and look forward to seeing additional data from the DREAM trial,” Maricich said in the statement.